Salute e Benessere

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR…

– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –– Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that address the underlying cause of the disease – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug.11, 2025(GLOBE NEWSWIRE) --Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a...
Nasdaq GlobeNewswire
11/08/2025

FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug…

Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumorsMilestone in drive to redefine cancer treatment with precision oncology therapyBasel, Switzerland – August 11, 2025– FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced...
Nasdaq GlobeNewswire
11/08/2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and…

Zymeworks Inc.(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company’s Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of...
Nasdaq GlobeNewswire
11/08/2025

Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global…

This partnership leverages IQVIA's deep expertise in global clinical trial design, regulatory strategy, and data-driven insights. By combining Kexing's innovative product pipeline with IQVIA's global operational infrastructure, the two companies aim to enhance trial efficiency, and enable faster access to international markets. The collaboration is expected to significantly strengthen Kexing's global development capabilities and accelerate its transition toward becoming an international…
PR Newswire
11/08/2025

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for…

WuXi Biologics developed WuXia293Stable by leveraging its proprietary HEK293 cell line. Derived from WuXi Biologics' highly-vetted mammalian cell line development platform family WuXia™, WuXia293Stable demonstrates productivity, quality and stability comparable to WuXia™ while maintaining full compatibility with its process, as shown by its robust growth and balanced metabolism. WuXi Biologics developed WuXia293 Stableby leveraging its proprietary HEK293 cell line. Derived from WuXi...
PR Newswire
11/08/2025

AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug…

A Paradigm Shift in Fat Reduction Therapy A Paradigm Shift in Fat Reduction Therapy Currently, the only FDA-approved injectable drug for localized fat reduction is based ondeoxycholic acid, which destroys fat cells throughnecrosis. While clinically effective, this cytolytic process causes strong inflammation, often resulting in pain,bruising, and prolongedswelling. In contrast, AYP-101 selectively inducesapoptosis, a natural and controlled form of programmed cell death that...
PR Newswire
11/08/2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint…

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease 1 Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s diseaseIanalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease 1,2 Novartis plans to present its data at an...
Nasdaq GlobeNewswire
11/08/2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates. Preliminary, Unaudited Second Quarter...
Nasdaq GlobeNewswire
11/08/2025

Idorsia publishes interim results of repurchase offer for its 2025 and 2028…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204 *million convertible bonds maturing in 2025 ( CB 2025 ; ISIN CH0426820350) and CHF 600 million convertible bonds maturing in 2028 ( CB 2028 ; ISIN CH1128004079) (theRepurchase Offer )launchedon June 25, 2025.As of the end of the main offer period, Bondholders have accepted the Repurchase Offer...
Nasdaq GlobeNewswire
11/08/2025

Philippines' AC Health partners with Singapore's ABC Impact in vision to…

The fresh capital will fuel AC Health's expansion across its core pillars of hospitals, multi-specialty clinics, and retail pharmacies – through a combination of organic initiatives and targeted acquisitions. By 2027, AC Health aims to expand its network to at least 10 hospitals, 300 clinics, and 1,150 pharmacies across the Philippines. The fresh capital will fuel AC Health's expansion across its core pillars of hospitals, multi-specialty clinics, and retail pharmacies – through a combination...
PR Newswire
11/08/2025

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing…

"Having worked with HistoIndex for many years, I have witnessed firsthand the value that Second Harmonic Generation imaging brings to fibrosis assessment in MASH clinical trials, with highly sensitive and consistent detection and quantification of fibrosis in liver biopsies. Automated solutions like FibroSIGHT™ Plus represent the future of liver pathology. The ability to detect incremental changes in fibrosis with this level of precision is exactly what we need to guide earlier and more…
PR Newswire
11/08/2025

Salama Announces Robust H1 2025 Performance Driven by Profitability and Equity…

Total Equity increased by 5.2 percent to AED 351.84 million as of June 30, 2025, from AED 334.38 million as of December 31, 2024, driven by profit generation and a reduction in accumulated losses to AED 440.68 million by June 30, 2025 from AED 443.86 million by the end of 2024. Bank balances and cash significantly improved to AED 214.44 million from AED 148.77 million at year-end 2024, reflecting robust cash management. Takaful service expenses saw a significant reduction, aligning with the…
PR Newswire
08/08/2025

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of…

INSIDE INFORMATION REGULATED INFORMATIONNyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that...
Nasdaq GlobeNewswire
08/08/2025

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally…

This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial 1 Accelerated approval follows Priority Review and Breakthrough Therapy Designation granted by the U.S. FDA for the treatment of patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer Ridgefield, Conn. U.S. and Ingelheim, Germany - Boehringer Ingelheim’s HERNEXEOS®...
Nasdaq GlobeNewswire
08/08/2025

Veterinary Diagnostics Market worth US$5.36 billion by 2030 with 7.8% CAGR |…

Browse in-depth TOC on "Veterinary Diagnostics Market" Browse in-depth TOC on "Veterinary Diagnostics Market" 775 - Tables66 - Figures585 - Pages By animal type,the veterinary diagnostics market is segmented into companion animals and livestock based on animal type. The companion animals segment accounted for the largest share of the market in 2024. The large share of this segment is attributed to the rising number of households owning pets such as dogs and cats...
PR Newswire
08/08/2025

From Little Threads to Big Dreams: LILYSILK Celebrates 15 Years of Innovation…

15 Years of Growth: Rooted in Craft, Reaching the World 15 Years of Growth: Rooted in Craft, Reaching the World At the heart of LILYSILK's success is an unwavering dedication to high-quality materials. From its signature Grade 6A mulberry silk to certified merino wool and cashmere, the brand continues to refine its craftsmanship. Today, LILYSILK products are backed by internationally recognized certifications, including OEKO-TEX, GOTS, GCS, and RWS, affirming its commitment to ethical...
PR Newswire
08/08/2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated...
Nasdaq GlobeNewswire
08/08/2025

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the…

® ) in combination with disitamab vedotin, an antibody-drug conjugate (“ADC”) developed by RemeGen Co., Ltd. as the treatment of HER2-expressing (HER2 expression is defined as a HER2 immunohistochemistry test result of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma (“UC”), has been accepted by the National Medical Products Administration (“NMPA”). This is toripalimab’s 13th application for marketing submitted in the Chinese mainland.UC is one of the ten most…
Nasdaq GlobeNewswire
08/08/2025

Vistin Pharma ASA: Invitation to Q2 2025 conference call

Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th of August 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The second quarter conference call will be available via web and audio through the following access points: Webcast: ...
Nasdaq GlobeNewswire
08/08/2025

Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on…

Tuesday, 19 August 2025 at 11.00 - 12.00h CESTIn connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call. The webcast of the conference call will be available during...
Nasdaq GlobeNewswire
08/08/2025

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

ORION CORPORATIONMANAGERS’ TRANSACTIONS8 AUGUST 2025 at 9.30 EEST Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the...
Nasdaq GlobeNewswire
08/08/2025

Nicox Extends Existing Flexible Equity Financing

Press ReleaseNicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025August 08, 2025 – release at 7:30 am Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of the PACEO 1equity line of financing entered into...
Nasdaq GlobeNewswire
08/08/2025

DermRays Celebrates 13 Years of Innovation with Advanced 810nm and 1064nm Diode…

Key Highlights of DermRays' 13-Year Journey: Key Highlights of DermRays' 13-Year Journey: To celebrate this milestone, DermRays is launching exclusive anniversary promotions discounts for the entire month of August, 2025. Customers are invited to join the celebration by sharing their success stories using #DermRays13 . "Thirteen years ago, we set out to democratize laser hair removal-making it accessible, safe, and effective for everyone," said Dr.Yang Lin, CEO of DermRays...
PR Newswire
08/08/2025

CHICAGO RIVER SWIM APPROVED FOR HISTORIC RETURN THIS SEPTEMBER

CHICAGO, Aug. 7, 2025 /PRNewswire/ -- The City of Chicago has officially approved the 2025 Chicago River Swim, the first organized open water swim in the river in nearly a century. Scheduled for Sunday, September 21, the event will highlight the city's environmental progress while raising funds for ALS research at Northwestern University'sFeinberg School of Medicine and youth swim safety education in underserved communities. CHICAGO , Aug. 7, 2025 /PRNewswire/ -- TheCity of Chicago...
PR Newswire
07/08/2025
Altri  Comunicati